

3 November 2025

MEDICAL SCIENCE LIAISON APPOINTED

- First dedicated Medical Science Liaison (MSL) appointed to lead national medical education and engagement programs.
- Expands EVE's medical capability following the launch of Dyspro™ and upcoming launch of Libbo™.
- Supports the Company's strategy to build confidence among prescribers and broaden patient access.
- Plans underway to expand the MSL team throughout 2026.

EVE Health Group Limited (ASX: EVE, EVE or the Company) is pleased to announce the appointment of a dedicated Medical Science Liaison (**MSL**). The MSL will lead education and engagement with general practitioners, specialists and nurse practitioners across Australia, supporting the growing clinical adoption of EVE's Dyspro™ and Libbo™ formulations for women's and men's health.

The appointment marks a significant step in EVE's commercial rollout strategy, providing direct scientific support and education to healthcare professionals. The role will focus on communicating the clinical benefits of EVE's formulations, facilitating training sessions, and ensuring prescribers are supported with the latest product data and patient outcomes.

EVE Chief Executive Officer, Damian Wood, said: "Building a dedicated MSL capability is an important milestone in EVE's evolution as a pharmaceutical company. Our goal is to make sure prescribers have the confidence and resources to use our products effectively. This appointment ensures we continue to back that growth with clinical education and medical engagement.

The MSL will work closely with the EVE team to expand prescriber networks and deliver education initiatives across key therapeutic areas. The Company anticipates expanding the MSL team across 2026 to support growing demand from healthcare professionals."

Authorised for release by the Board of Directors.

Company enquiries

+61 8 6465 5500
info@evehealthgroup.com.au

About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian life sciences company focused on developing and commercialising innovative pharmaceutical solutions in high-growth therapeutic areas. The company's lead assets include Dyspro, a fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo, an oral dissolving film for erectile dysfunction designed to deliver rapid onset and improved patient convenience. Both products leverage EVE's proprietary formulation and delivery technologies to enhance bioavailability and clinical outcomes, representing near-term commercial opportunities in large, underserved global markets.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.